Form 4: Exelixis Director Maria C. Freire Reports Stock Transactions

Director Maria C. Freire reports exercising stock options and selling shares of Exelixis, Inc. common stock on February 14, 2025.

Summary

• On February 14, 2025, Maria C. Freire, a director of Exelixis, Inc., executed transactions involving the company's common stock.
• Freire exercised options to acquire 15,874 shares at $20.50 and 28,240 shares at $22.10.
• She then sold 44,114 shares at a weighted average price of $34.94, with individual sales ranging from $34.92 to $35.02.
• Following these transactions, Freire directly owns 91,007 shares of Exelixis common stock, which includes 18,838 shares issuable upon vesting of restricted stock units.
• She also holds options to purchase 0 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, which is a common occurrence for publicly traded companies. It provides transparency into the trading activities of company directors and officers.

Comparison to Industry Standards

• Form 4 filings are standard practice for directors and officers of publicly traded companies like Exelixis, similar to filings made by insiders at companies like Amgen, Gilead Sciences, and Biogen.
• The reporting requirements are consistent across the industry, ensuring transparency in insider trading activities.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they reflect insider trading activity, but the overall impact is likely minimal given the volume of shares traded relative to the company's total outstanding shares.

Key Dates

Keywords

Exelixis, Director, Stock Options, Common Stock, Form 4, SEC, Maria C. Freire, Transactions